Evidence map›Paper›PMID 40281443›Full record

ArticleBMC cancer2025

Suppressor protein plasma levels and inflammatory indices in colorectal cancer patients.

Nino Chigvinadze, Ia Pantsulaia, Teimuraz Lejava, Archil Aladashvili, Tsitsino Atamashvili, Nino Khvichia, Khatuna Rekhviashvili

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nino ChigvinadzeDepartment of Genetics, Ivane Javakhishvili Tbilisi State University, Tbilisi, 0186, Georgia.
Ia PantsulaiaVl. Bakhutashvili Institute of Medical Biotechnology, Tbilisi State Medical University, Tbilisi, 0159, Georgia. i.pantsulaia@tsmu.edu.
Teimuraz LejavaDepartment of Genetics, Ivane Javakhishvili Tbilisi State University, Tbilisi, 0186, Georgia.
Archil AladashviliVl. Bakhutashvili Institute of Medical Biotechnology, Tbilisi State Medical University, Tbilisi, 0159, Georgia.
Tsitsino AtamashviliVl. Bakhutashvili Institute of Medical Biotechnology, Tbilisi State Medical University, Tbilisi, 0159, Georgia.
Nino KhvichiaDepartment of Genetics, Ivane Javakhishvili Tbilisi State University, Tbilisi, 0186, Georgia.
Khatuna RekhviashviliVl. Bakhutashvili Institute of Medical Biotechnology, Tbilisi State Medical University, Tbilisi, 0159, Georgia.

Funding

Shota Rustaveli National Science Foundation (SRNSF) PHDF-21-1886
6 · The paper itself

Abstract

Colorectal cancer (CRC) is a multifactorial and age-related disease. Additionally, age, sex, and risk factors for developing CRC may include genetic, epigenetic, and immunologic characteristics and lifestyle habits. Simultaneous examination of gene mutations and their products is vital for determining patient prognosis and treatment. Therefore, we assessed APC, KRAS, and TP53 plasma levels; inflammatory indices; and KRAS mutations in CRC patients and evaluated their role in cancer progression. The study population consisted of colorectal cancer patients (40 patients: 16 women and 24 men). KRAS mutations were detected using real-time PCR; APC, KRAS, and TP53 protein levels were measured via ELISA. The results revealed that inflammatory indices (MLR, PLR, NLR) are increased in CRC patients, especially in those with advanced stages. TP53 protein levels were increased in patients with progressive cancer, whereas no significant difference was detected in the plasma levels of APC and KRAS. The G12V KRAS mutation was associated with a poor prognosis and high PLR values. Our findings reveal that inflammatory indices such as the MLR, PLR, and NLR are linked to TP53 and APC plasma levels and offer new insights into their role in the development and progression of CRC.

Indexed as

Adenomatous Polyposis Coli ProteinBiomarkers, TumorColorectal NeoplasmsInflammationProto-Oncogene Proteins p21(ras)Tumor Suppressor Protein p53AdultAgedDisease ProgressionFemaleHumansMaleMiddle AgedMutationNeoplasm StagingPrognosisAdenomatous Polyposis Coli ProteinAPC protein, humanBiomarkers, TumorKRAS protein, humanProto-Oncogene Proteins p21(ras)TP53 protein, humanTumor Suppressor Protein p53Colorectal cancerInflammatory indicesKRAS gene mutationsSuppressor protein

Identifiers

PMID40281443
PMCPMC12023565

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.